OHC invites you to a free community panel discussion about breast health and cancer that features two of the area’s most prominent oncologists specializing in women’s health. In addition to an energetic panel discussion, you’ll get   (Read More)

According to OHC Chief Medical Officer Dr. David Kirlin, the OHC Kenwood office (located in Mercy Hospital, Kenwood) will now offer expanded hours to its patients on weekends, beginning this weekend (Oct. 5 and 6). The new weekend program is part of   (Read More)

Progress continues fast and furious on the OHC West medical office building, located on Mercy Health’s new West Hospital campus just two blocks from the Routes 74/52 and North Bend Road junction in Monfort Heights. Under the watchful eyes of   (Read More)

Cancer care teams and patients on Cincinnati’s Westside will be coming together soon as construction moves quickly on the completion of our new, state-of-the-art OHC West office — conveniently located on Mercy Health’s new West Hospital campus.   (Read More)

Our own Dr. Dyehouse appeared as a guest on The Morning Show with Brian Thomas on 55KRC. Listen to the interview from July 30 here. She covers everything from our leadership in clinical trials and compassion in cancer care to coordinated healthcare   (Read More)

OHC offers the Greater Cincinnati area the largest group of Medical Oncology specialists providing access to cutting-edge research. Participating in clinical trials allows patients access to new treatments before they are widely available and helps   (Read More)

OHC is expanding. Soon, we will be serving our patients in the Mt. Airy, Rapid Run, and Western Hills areas. “OHC West” will operate on the first two floors of a five-story medical office building adjacent to the new Mercy Health-West Hospital in   (Read More)

Cincinnati Magazine’s 2013 Top Doctors list includes 26 OHC physicians — more than half of its physicians. The magazine surveyed more than 5,000 medical doctors in our region to determine whom they would turn to if they, a family member, or a   (Read More)

OHC participated in the clinical trial titled, “A Single-Arm, Open-Label, Expanded Access Study of RO5185426 in Patients with Metastatic Melanoma.” The purpose of this clinical trial was to allow access to this study drug to patients in which   (Read More)

OHC participated in the clinical trial titled, “A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based   (Read More)